Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Byung Sup | - |
dc.contributor.author | Seol, Ho Jun | - |
dc.contributor.author | Nam, Do-Hyun | - |
dc.contributor.author | Park, Chul-Kee | - |
dc.contributor.author | Kim, Il Han | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Jeong Hoon | - |
dc.contributor.author | Cho, Young Hyun | - |
dc.contributor.author | Yoon, Sang Min | - |
dc.contributor.author | Chang, Jong Hee | - |
dc.contributor.author | Kang, Seok-Gu | - |
dc.contributor.author | Kim, Eui Hyun | - |
dc.contributor.author | Suh, Chang-Ok | - |
dc.contributor.author | Jung, Tae-Young | - |
dc.contributor.author | Lee, Kyung-Hwa | - |
dc.contributor.author | Kim, Chae-Yong | - |
dc.contributor.author | Kim, In Ah | - |
dc.contributor.author | Hong, Chang-Ki | - |
dc.contributor.author | Yoo, Heon | - |
dc.contributor.author | Kim, Jin Hee | - |
dc.contributor.author | Kang, Shin-Hyuk | - |
dc.contributor.author | Kang, Min Kyu | - |
dc.contributor.author | Kim, Eun-Young | - |
dc.contributor.author | Kim, Sun-Hwan | - |
dc.contributor.author | Chung, Dong-Sup | - |
dc.contributor.author | Hwang, Sun-Chul | - |
dc.contributor.author | Song, Joon-Ho | - |
dc.contributor.author | Cho, Sung Jin | - |
dc.contributor.author | Lee, Sun-Il | - |
dc.contributor.author | Lee, Youn-Soo | - |
dc.contributor.author | Ahn, Kook-Jin | - |
dc.contributor.author | Kim, Se Hoon | - |
dc.contributor.author | Lim, Do Hun | - |
dc.contributor.author | Gwak, Ho-Shin | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Hong, Yong-Kil | - |
dc.date.accessioned | 2021-09-03T11:26:15Z | - |
dc.date.available | 2021-09-03T11:26:15Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/85034 | - |
dc.description.abstract | Purpose The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. Materials and Methods A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. Results After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. Conclusion Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | RECURSIVE PARTITIONING ANALYSIS | - |
dc.subject | MGMT PROMOTER METHYLATION | - |
dc.subject | HIGH-GRADE GLIOMAS | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | MALIGNANT GLIOMA | - |
dc.subject | SURVIVAL | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | RESECTION | - |
dc.subject | EXTENT | - |
dc.subject | INACTIVATION | - |
dc.title | Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Shin-Hyuk | - |
dc.identifier.doi | 10.4143/crt.2015.473 | - |
dc.identifier.scopusid | 2-s2.0-85010310525 | - |
dc.identifier.wosid | 000391899800021 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.49, no.1, pp.193 - 203 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 49 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 193 | - |
dc.citation.endPage | 203 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002190173 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | RECURSIVE PARTITIONING ANALYSIS | - |
dc.subject.keywordPlus | MGMT PROMOTER METHYLATION | - |
dc.subject.keywordPlus | HIGH-GRADE GLIOMAS | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | MALIGNANT GLIOMA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | EXTENT | - |
dc.subject.keywordPlus | INACTIVATION | - |
dc.subject.keywordAuthor | Glioblastoma | - |
dc.subject.keywordAuthor | Temozolomide | - |
dc.subject.keywordAuthor | MGMT | - |
dc.subject.keywordAuthor | Chemoradiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.